Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2009-01-22
2010-11-23
Martinell, James (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100
Reexamination Certificate
active
07838240
ABSTRACT:
Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and/or extent of a MN/CA9 gene expression product in a sample from the affected subject, wherein if 50% or fewer cells are found to express the MN/CA9 gene, then the subject is considered to have a poorer prognosis. MN/CA9 gene expression products useful in the prognostic methods include MN protein, MN polypeptide and/or MN nucleic acids. The methods are useful as an aid in the selection of treatment for a patient with renal cell carcinoma, alone or in combination with conventional tumor stage and/or grade information. The methods of the invention can be used, for example, to identify those patients requiring more aggressive therapy regimens, or those patients most likely to respond to adjuvant immunotherapies, particularly MN/CA IX/CA9-targeted therapies.
REFERENCES:
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5955075 (1999-09-01), Zavada et al.
patent: 5972353 (1999-10-01), Zavada et al.
patent: 6004535 (1999-12-01), Zavada et al.
patent: 7482129 (2009-01-01), Soyupak et al.
patent: 2005/0158809 (2005-07-01), Bui et al.
patent: WO 93/18152 (1993-09-01), None
patent: WO 95/34650 (1995-12-01), None
patent: WO 00/24913 (2000-05-01), None
patent: WO 03/089659 (2003-10-01), None
patent: WO 03/100029 (2003-12-01), None
Bui et al, Clin. Cancer Res. 9: 802 (2003).
Brewer et al., “A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MN,”Gynecologic Oncology, 63: 337-344 (1996).
Bui et al., “Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy,”Clin. Cancer Res., 9(2): 802-811 (2003).
Bui et al., “Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma,”J. Urol., 171: 2461-2466 (2004).
Bui et al., “Prognostic factors and molecular markers for renal cell carcinoma,”Expert Rev. Anticancer Ther., 1(4): 565-575 (2001).
Chia et al., “Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma,”J. Clin. Oncol., 19: 3660-3668 (2001).
Divgi et al., “Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma,”Clin. Cancer Res., 4: 2729-2739 (1998).
Fuhrman et al., “Prognostic significance of morphologic parameters in renal cell carcinoma,”Am. J. Surg Pathol., 6: 655-663 (1982).
Giatromanolaki et al. “Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer,”Cancer Res., 7992-7998 (2001).
Ivanov et al., “Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes,”Proc. Natl. Acad. Sci. (USA), 95: 12596-12601 (1998).
Ivanov et al., “Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer,”Am. J. Pathol., 158: 905-919 (2001).
Jocham et al, “Adjuvant autologous renal tumor cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial,”Lancet, 363: 594-599 (2004).
Kim et al., “Using protein expressions to predict survival in clear cell renal carcinoma,”Clin. Cancer Res., 10(16): 5464-5471 (2004).
Kim et al., “Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma,”J. Urol., 173(5): 1496-1501 (2005).
Koukourakis et al., “Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy,”Clin. Cancer Res., 7: 3399-3403 (2001).
Liao and Stanbridge, “Expression of the MN Antigen in Cervical Papanicolaou Smears Is an Early Diagnostic Biomarker of Cervical Dysplasia,”Cancer Epidemiology, Biomarkers&Prevention, 5: 549-557 (1996).
Liao et al., “Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas,”Am. J. Pathol., 145: 598-609 (1994).
Liao et al., “Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney,”Cancer Res., 57: 2827-2831 (1997).
Loncaster et al., “Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix,”Cancer Res., 61: 6394-6399 (2001).
McKiernan et al., “Expression of the Tumor-associated GeneMN: A Potential Biomarker for Human Renal Cell Carcinoma,”Cancer Res., 57: 2362-2365 (1997).
Murakami et al., “MN/CA9gene expression as a potential biomarker in renal cell carcinoma,”BJU Int., 83: 743-747 (1999).
Novick and Campbell,Renal tumors; in Walsh, P., editor, Campell's Urology, Philadelphia: Saunders, pp. 2672-2731 (2002).
Oosterijk et al., “Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney,”Int. J. Cancer, 38: 489-494 (1986).
Pastorek et al., “Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helex-loop-helix DNA binding segment,”Oncogene, 9: 2877-2888 (1994).
Pastorekova and Zavada, “Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy,”Cancer Therapy, 2: 245-262 (2004).
Pastorekova et al., “A novel quasi-viral agent, MaTu, is a two-component system,”Virology, 187: 620-626 (1992).
Pastorekova et al., “Carbonic Anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts,”Gastroenterology, 112: 398-408 (1997).
Potter and Harris, “Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer,”Br. J. Cancer, 89: 2-7 (2003).
Rioux-Leclercq et al., “Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma,”Urology, 55(4): 501-505 (2000).
Saarino et al., “Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation,”Am. J. Pathol., 153: 279-285 (1998).
Swinson et al., “Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small cell lung cancer,”J. Clin. Oncol., 21: 473-482 (2003).
Tso et al., “Induction of G250-targeted and T-cell mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor,”Cancer Res., 7925-7933 (2001).
Tsui et al., “Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria,”J. Urol., 163(4): 1090-1095 (2000).
Uemura et al., “Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target,”J. Urol., 157 (4 Suppl.): 377 (Abstract 1475; 1997).
Uemura et al., “MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas,”Br. J. Cancer, 81: 741-746 (1999).
Wingo et al., “The catalytic properties of human carbonic anhydrase IX,”Biochem. Biophys. Res. Commun., 288: 666-669 (2001).
Wykoff et al. “Hypoxia-inducible expression of tumor-associated carbonic anhydrases,”Cancer Res., 60: 7075-7083 (2000).
Zavada et al.,
Erdo{hacek over (g)}an Seyda
Soyupak Bülent
Harland Joan C.
Institute of Virology of the Slovak Academy of Sciences
Lauder Leona L.
Martinell James
Shimei Barbara A.
LandOfFree
MN/CA IX/CA9 and renal cancer prognosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MN/CA IX/CA9 and renal cancer prognosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MN/CA IX/CA9 and renal cancer prognosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4233041